2023
DOI: 10.1016/j.molliq.2023.121345
|View full text |Cite
|
Sign up to set email alerts
|

Rational approaches to discover SARS-CoV-2/ACE2 interaction inhibitors: Pharmacophore-based virtual screening, molecular docking, molecular dynamics and binding free energy studies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 49 publications
0
2
0
Order By: Relevance
“…The combination of the 3D-RISM with bioinformatics tools assumes the use of extensive data sets. Despite recent progress in virtual screening and machine learning for virus-ligand complexes (see, for instance, [114][115][116][117]), information about the actual conformation of hydrated virus complexes is rather limited so far. However, we can make the following statement based on our own results [5,37,40] and comparative analysis of data from various computational methods [118] for proteins and solvated protein-ligand complexes.…”
Section: Discussionmentioning
confidence: 99%
“…The combination of the 3D-RISM with bioinformatics tools assumes the use of extensive data sets. Despite recent progress in virtual screening and machine learning for virus-ligand complexes (see, for instance, [114][115][116][117]), information about the actual conformation of hydrated virus complexes is rather limited so far. However, we can make the following statement based on our own results [5,37,40] and comparative analysis of data from various computational methods [118] for proteins and solvated protein-ligand complexes.…”
Section: Discussionmentioning
confidence: 99%
“…Several specific anti-COVID-19 treatments are in development, including promising small interfering RNA (siRNA)-based therapies. 13 , 14 , 15 These siRNAs, utilizing the RNA interference (RNAi) machinery, degrade viral RNAs and can be swiftly adapted to target emerging variants. 10 , 16 There is significant interest in RNAi-based therapeutics for COVID-19, especially targeting the viral RNA-dependent RNA polymerase (RdRp), a key replication enzyme.…”
Section: Introductionmentioning
confidence: 99%